Ratings by Morgan Stanley (Maxwell Skor)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/25/2026 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/11/2026 | CRISPR Therapeutics | CRSP | New Coverage | Equalweight (N/A) |
51.48 (47.78) |
-7.19% | Details | |
| 5/6/2026 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/16/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2026 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/2/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/30/2026 | Insmed | INSM | Upgrade | Overweight (Equalweight) |
147.60 (108.32) |
-26.61% | Details | |
| 3/17/2026 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/13/2026 | Sana Biotechnology | SANA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/2/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2026 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/12/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2026 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/9/2026 | Monopar Therapeutics | MNPR | New Coverage | Overweight (N/A) |
65.01 (111.12) |
70.93% | Details | |
| 12/23/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 12/4/2025 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2025 | Cidara Therapeutics | CDTX | Downgrade | Equalweight (Overweight) |
105.99 (221.38) |
108.87% | Details | |
| 11/14/2025 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2025 | Tscan Therapeutics Inc | TCRX | Downgrade | Equalweight (Overweight) |
1.19 (0.91) |
-23.53% | Details | |
| 10/31/2025 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/16/2025 | Cidara Therapeutics | CDTX | New Coverage | Overweight (N/A) |
110.64 (105.99) |
-4.2% | Details | |
| 8/20/2025 | Insmed | INSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/13/2025 | Insmed | INSM | Downgrade | Equalweight (Overweight) |
112.89 (147.60) |
30.75% | Details | |
| 7/17/2025 | Amicus Therapeutics | FOLD | Upgrade | Overweight (Equalweight) |
5.91 (14.49) |
145.18% | Details | |
| 7/3/2025 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
172.00 (261.00) |
51.74% | Details | |
| 7/3/2025 | Sana Biotechnology | SANA | New Coverage | Overweight (N/A) |
2.83 (3.15) |
11.31% | Details | |
| 5/8/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2025 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2025 | Cytokinetics | CYTK | New Coverage | Overweight (N/A) |
43.27 (80.18) |
85.3% | Details | |
| 8/19/2024 | Invivyd Inc. | IVVD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/26/2024 | Invivyd Inc. | IVVD | Upgrade | Overweight (Equalweight) |
4.36 (0.74) |
-83.03% | Details | |
| 12/7/2023 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2023 | Pharvaris B.V. | PHVS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | Vaccitech | VACC | Downgrade | Equalweight (Overweight) |
1.69 (5.00) |
195.86% | Details | |
| 8/15/2023 | Pharvaris B.V. | PHVS | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/15/2023 | Pharvaris B.V. | PHVS | Upgrade | Overweight (Equalweight) |
18.56 (34.94) |
88.25% | Details |
